ITOCD Event 2012

Agenda

Opening Remarks and Key Note Lecture on Cancer Biology

 

08:00 - 08:30

Opening Remarks

 

08:30 - 09:15

Key Note Lecture on Cancer Biology

Ectopic expression of protein elongation factors - a new Hallmark for lung and other cancers

A. F. Gazdar, Dallas

View slides (PDF)

 

Targeting Tumor Angiogenesis: Molecular Biology and Clinical Practice

Chairs: N. Saijo, Tokyo / G. Scagliotti, Torino

 

09:15 - 09:30

Angiogenesis and the metastatic process

F. Bussolino, Torino

View slides (PDF)

 

09:30 - 09:45

Angiogenesis and biomarker-profiling

J. Heymach, Houston

 

09:45 - 10:00

Molecular Imaging and anti-angiogenic therapy

T. Henzler, Mannheim

 

10:00 - 10:15

Mechanism of resistance to anti-angiogenic agents

M. Edelman, Baltimore

View slides (PDF)

 

10:15 - 10:30

Integrin inhibitors

S. Peters, Lausanne

View slides (PDF)

 

10:30 - 10:45

Anti-angiogenic TKI's

J.Y. Doulliard, Nantes

View slides (PDF)

 

10:45 - 11:15

Discussant: A. B. Sandler, Portland

 

Boehringer-Ingelheim Symposium

Let's Work: Individualized therapy today & tomorrow

Chairs: C. Manegold, Mannheim

 

11:30 - 12:30

First Look then Cook: Getting molecular testing into clinical routine

J. Wolf, Cologne

View slides (PDF)

 

Four in One Go- The benefits of irreversible ErbB-family blockade

O. Zaba, Berlin

View slides (PDF)

 

Fiat LUX- The Afatinib- Lung Cancer LUX-lung study programme

R. Wiewrodt, Münster

View slides (PDF)

 

Abbott Symposium

Molecular pathology to determine responders to targeted therapies in NSCLC

Chair: K. O‘Byrne, Dublin

View slides (PDF)

 

12:45 - 13:45

Targeting patients

K. O'Byrne, Dublin

 

Challenges in pathology

K. Kerr, Aberdeen

 

How to detect ALK rearrangements

P. Pauwels, Antwerp

 

Novel Agents I

Chairs: W. Eberhardt, Essen / T. Le Chevalier, Paris

 

14:45 - 15:00

Heat shock protein targeting agents

K. O'Byrne, Dublin

 

15:00 - 15:15

PARP1-inhibition

T. Helleday, Stockholm

View slides (PDF)

 

15:15 - 15:30

Dendritic cell mediated immunotherapy (DCMI)

A. Y. Chang, Singapore

View slides (PDF)

 

15:30 - 15:45

Vaccine therapy

J. Vansteenkiste, Leuven

View slides (PDF)

 

15:45 - 16:00

C-met inhibition in lung cancer

S. Novello, Torino

View slides (PDF)

 

16:00 - 16:15

EC145 folate-receptor targeted vinca-alkaloid conjugate and Tc99EC20 imaging: early clinical data

M. Edelmann, Balitmore

View slides (PDF)

 

16:15 - 16:45

Discussion

 

Mannheim Lilly Oncology Lecture

 

08:00 - 08:45

Genomics in Lung Cancer

R. Thomas, Cologne

View slides (PDF)

 

Presidential Symposium

Issues in the medical treatment of advanced NSCLC

Chairs: C. Manegold, Mannheim / L. Paz-Ares, Seville

 

12:15 - 13:15

The potential of small pre-operative trials for the development of new agents in early stage diseasev

V. Westeel, Besancon

View slides (PDF)

 

Clinical evidence for extending induction chemotherapy beyond 4-6 cycles in advanced non-mutated, non-squamous disease

C. Belani, Hershey

View slides (PDF)

 

How to individualize antineoplastic therapy in elderly patients

C. Gridelli, Avellino

View slides (PDF)

 

Hoffmann- La Roche Symposium

Debating therapy in lung cancer: where are we today?

Chair: R. Perez-Soler, New York

 

13:30 - 14:30

The evolving treatment landscape of NSCLC

R. Perez-Soler, New York

 

Achieving responses and improving patient outcomes

A. M. Dingemans, Maastricht

 

New perspectives in NSCLC maintenance therapy

F. Barlesi, Marseille

 

The debate: shifting the NSCLC treatment paradigm

Faculty and Audience

 

Gene Expression / Proteomics / Tumor Histology Guided Therapy

Issues in the medical treatment of advanced NSCLC

Chairs: N. van Zandwijk, Sydney / J. Niklinski, Bialystok

 

14:45 - 15:15

Proteomics: Ready for prime time?

D. Carbone, Nashville

View slides (PDF)

 

15:15 - 15:30

The role of immunohistochemistry in prognosis and prediction

F. Hirsch, Denver

View slides (PDF)

 

15:30 - 15:45

Techniques to diagnose ALK-Translocation

P.-C. Yang, Taipei

View slides (PDF)

 

15:45 - 16:00

Genomic characterization and targeted therapies for squamous cell carcinoma of the lung

P. Hammerman, Boston

View slides (PDF)

 

16:00 - 16:15

Treatment selection by ERCC1 expression /RRM1 expression: The MADEiT and the EPIC study

G. Simon, Houston

View slides (PDF)

 

16:15 - 16:30

Characterization of adenoma-carcinoma

E. Thunnissen, Amsterdam

View slides (PDF)

 

16:30 - 16:45

Biomarker –driven studies

B. Besse, Villejuif

View slides (PDF)

 

16:45 - 17:15

Discussant: K. Kerr, Aberdeen

View slides (PDF)

 

Meet the Professor Session

 

08:00 - 08:45

Management of bone metastasis:

P. Harper, London

 

Procurement, Processing and interpretation of small biopsy specimen

M. Papotti, Torino

 

Novel Agents II

Chairs: J.S. Lee, Seoul / P. Bunn, Denver

 

09:00 - 09:15

Window of opportunity trials for targeted therapies

M. Kris, New York

View slides (PDF)

 

09:15 - 09:30

AKT, MAPK, MEK-inhibitors

A. Adjei, Buffalo

View slides (PDF)

 

09:30 - 09:45

ALK, ROS 1-inhibitors

L. Crino, Perugia

View slides (PDF)

 

09:45 - 10:00

SRC-targeting agents

O. Gautschi, Bern

View slides (PDF)

 

10:00 - 10:15

IGFR-inhibitors: End of a targeted therapy?

S. Ramalingam, Atlanta

View slides (PDF)

 

10:15 - 10:30

Apoptotic agents

D. Fennell, Leicester

View slides (PDF)

 

10:30 - 10:45

NCI-Canada Clinical trials investigating targeted therapies

G. Goss, Ottawa

View slides (PDF)

 

10:45 - 11:00

Discussant: L. Paz-Ares, Sevilla

 

Tabacco Control and Lung Cancer Prevention

Chairs: P. Postmus, Amsterdam / Y.L. Wu, Guangzhou

 

11:30 - 11:45

Implementation of smoking cessation: achievements and hurdles

J. Jassem, Gdansk

View slides (PDF)

 

11:45 - 12:00

Smoking cessation efforts in Asia

C. Zhou, Shanghai

View slides (PDF)

 

12:00 - 12:15

Lung Cancer survival-regional differences

C. M. Dresler, Little Rock

View slides (PDF)

 

12:15 - 12:30

Chemoprevention: Lessons from randomized trials

Y. E. Miller, Denver

View slides (PDF)

 

12:30 - 12:45

Molecular mechanism of chemopreventive compounds and novel approaches to assess efficacy

F. R. Khuri, Atlanta

View slides (PDF)

 

12:45 - 13:00

Incorporating tobacco control into lung cancer screening programs

P. Boffetta, New York

View slides (PDF)

 

13:00 - 13:15

Discussion

 

Challenges in Thoracic Oncology I

Chairs: D. H. Grunenwald, Paris / K. Syrigos, Athens

 

14:15 - 14:30

New TNM classification: Achievements and hurdles

P. Goldstraw, London

View slides (PDF)

 

14:30 - 14:45

Post-operative PET/CT for early detection of NSCLC recurrence

S. Schönberg, Mannheim

View slides (PDF)

 

14:45 - 15:00

EBUS and EUS for N-staging

F. Herth, Heidelberg

 

15:00 - 15:15

Lung cancer in never smokers – prognostic and therapeutic implications

K. Park, Seoul

View slides (PDF)

 

15:15 - 15:30

Is there a role of induction therapy?

P. van Schil, Antwerp

 

15:30 - 15:45

Malignant pleural mesothelioma: P/D vs EPP

W. Weder, Zurich

View slides (PDF)

 

15:45 - 16:00

Discussion

 

Challenges in Thoracic Oncology II

Chairs: F. Mornex, Lyon / C. Manegold, Mannheim

 

14:15 - 14:30

Stereotactic ablative radiation therapy (SABR) for NSCLC: Patient selection and fractionation regimes

S. Senan, Amsterdam

 

14:30 - 14:45

New radiotherapy techniques

U. Ricardi, Torino

View slides (PDF)

 

14:45 - 15:00

Potential toxicity of PCI

F. Wenz, Mannheim

View slides (PDF)

 

15:00 - 15:15

Update of thymoma management

A. Marx, Mannheim

View slides (PDF)

 

15:15 - 15:30

Clinical approaches to K-ras mutant NSCLC

E. Smit, Amsterdam

View slides (PDF)

 

15:30 - 15:45

Biomarkers in malignant pleural mesothelioma and treatment prediction

V. Surmont, Gent

View slides (PDF)

 

15:15 - 15:30

Is the treatment of SCLC heading through new pathways?

A. Ardizzoni, Parma

View slides (PDF)

 

15:45 - 16:00

Closing Remarks

C. Manegold, Mannheim

 

 

 

About us

PEKKIP Congress GmbH is responsible for planning, executing and following up high-class medical conventions, training courses, advisory boards and networking events.

A brief history overview

Did you miss one of our events or would like to review some of the information from past conventions? It doesn’t get easier than this. Simply read through all the details here.

There’s always someone around to serve you. 

Do you have questions about our offers or need more information on one of our events? Give us a ring on +49 (0)6221 655 700, and we will be happy to help you.

Additional ways to contact us